Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Opexa Therapeutics

Biogen Idec building

Biogen’s CEO Scangos to step down

Departure comes as multiple sclerosis drug Tecfidera achieves improved sales growth

Novartis Gehry Building

New drugs help Novartis shrug off Gleevec competition

However, warns of lesser profits this year as firm looks to boost promotion of Entresto

Roche Basel Switzerland

Roche’s MS drug Ocrevus awarded priority review by FDA

Comes as Swiss company files the therapy with the FDA and EMA

Merck’s accelerator to take start-ups to Silicon Valley

Will expand the reach of its Darmstadt and Nairobi programmes

Biogen Idec building

Biogen multiple sclerosis drug flunks clinical trial

Opicinumab had been proposed as a possible reparative therapy in MS

- PMLiVE

Sanofi Genzyme launches multiple sclerosis awareness campaign

Aims to highlight and address the physical and emotional burden of the disease

Biogen Idec building

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Once-monthly, self-administered Zinbryta ‘significantly’ reduces relapse rate

- PMLiVE

Merck agrees African digital cooperation deal

Will collaborate with Germany's GIZ on new solutions for the continent

- PMLiVE

Women’s well-being needs are broader than health

Merck event hears how women’s and government priorities are often mismatched

- PMLiVE

Biogen targets ‘lost to follow-up’ patients in MS campaign

Biotech company's 1MSg initiative will provide a range of educational materials

- PMLiVE

Roche and AZ claim FDA breakthrough status for new drugs

Designation could speed up development for Roche’s ocrelizumab and AZ’s durvalumab 

- PMLiVE

UK government fines GSK over ‘pay-for-delay’ deals

Merck KGaA and Actavis also fined for their involvement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links